

## Accelerating Patient Enrolment at Scale Through a Bespoke Clinical User Interface

How a custom-built interface allowed CG Oncology to speed up patient onboarding and remove operational bottlenecks across bladder cancer trials



### Executive Summary

CG Oncology faced a growing operational challenge. As patient enrolment increased across multiple bladder cancer trials, the manual process for reviewing each patient consumed five to six hours of clinician time. The organisation needed a way to scale without adding headcount or risking delays in critical trials.

Peraison partnered with CG Oncology to design and deliver a custom web application built using Angular and .NET Core to transform a fragmented, manual workflow into a streamlined digital process.

The result was a dramatic shift: patient reviews that once took hours were completed in minutes. The platform equipped CG Oncology to accelerate trial timelines and manage onboarding at scale with confidence.

### The Challenge

Patient enrolment is one of the most persistent bottlenecks in clinical research. For CG Oncology, a late-stage biopharmaceutical company focused on bladder-sparing therapeutics, this challenge was intensified by the complexity of the documentation required for each patient.

#### Clinical teams had to:

- Piece together unstructured records from different formats
- Manually separate large PDF packs into usable documents
- Repeatedly chase sites for missing details
- Perform eligibility checks without a unified, traceable system

Each review took hours. As multiple trials moved into high-volume enrolment, CG Oncology faced mounting pressure to scale operations without compromising accuracy or compliance.

The business problem was clear: enrolment speed was limiting the organisation's ability to advance trials efficiently.

# Accelerating Patient Enrolment at Scale Through a Bespoke Clinical User Interface

## The Solution

Peraison designed a bespoke front-end application that brought structure, visibility and automation into the onboarding workflow.

### Custom-built for clinical teams

The interface, created using Angular and .NET Core, was tailored to the client's real workflow. It presented patient information, documents, AI generated profiles and eligibility assessments in a streamlined, intuitive format.

### Optimised for adoption


The web-based application required no installation and felt like a polished product rather than a prototype. This ensured rapid adoption among clinical teams and site coordinators.

### Deeply integrated with Snowflake

Through secure Snowflake APIs, the front-end allowed users to interact directly with data extracted and processed inside Snowflake.

### Designed for scale

Because the front-end was both modular and flexible, the platform could grow with the client's trials and be extended to new therapeutic areas or partners.



The screenshot displays the Peraison web application interface. At the top, there is a navigation bar with the Peraison logo and user options like 'Participants', 'Documents', and 'Admin'. Below this is a 'Search Participant' section with a search input field and a list of participant IDs (9112005, 9125001, 9142004) with their respective dates. The main content area shows a 'Medical Status Analysis' table with the following structure:

Inclusion Criteria	Extracted Status	AI Generated Status	Final Status	Validated	Comments
Be >?(18) years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> <a href="#">View Evidence</a>	<input type="checkbox"/>	<input type="checkbox"/>	Enter your comments here...
Have Eastern Cooperative Oncology Group (ECOG) performance status of ??(0) to ??(2).	<input checked="" type="checkbox"/>	<input type="checkbox"/> <a href="#">View Evidence</a>	<input type="checkbox"/>	<input type="checkbox"/>	Enter your comments here...
Has the below, pathologically confirmed within 12 weeks of study randomization - Recurrent low-grade Ta within 12 months of prior low-grade or high-grade (high-grade Ta [HG Ta] ≤ 3 cm) tumor. - Solitary low-grade Ta >3 cm. - Multifocal low-grade Ta. - Primary and solitary HG Ta ≤ 3 cm. - Low-grade T1. Note: To adequately rule out T2 disease, the T1 pathology specimen should include muscle fibers.	<input checked="" type="checkbox"/>	<input type="checkbox"/> <a href="#">View Evidence</a>	<input type="checkbox"/>	<input type="checkbox"/>	Enter your comments here...

# Accelerating Patient Enrolment at Scale Through a Bespoke Clinical User Interface

## The Impact

### Hours reduced to minutes

Automated document ingestion, profiling and eligibility review cut onboarding time dramatically, freeing clinicians to focus on decision-making rather than administration.

### Ability to scale trials without increasing headcount

CG Oncology could take on larger cohorts and run more concurrent trials because the workflow no longer depended solely on manual labour.

### Improved site relationships

Faster and clearer feedback reduced the number of follow-up queries and improved collaboration across trial sites.

### A product-ready platform with commercial potential


The solution delivered a production-grade eligibility assessment system that CG Oncology can now productise as part of its value proposition to partners and sponsors.

### A reliable foundation for future innovation

With Snowflake as the unified data hub and a custom interface tailored to real-world workflows, CG Oncology now has an infrastructure that supports long-term operational excellence.

Author

**Sofia Silva,**  
Senior Consultant

PERAISON | Participants | Documents | Admin

Search Participant

Search ...

3 results | Order By ▾

9112005	Pathology Expires: 4 Mar 2025	Documents	Participant Profile	Medical Status	Generate Full Report
9125001	Pathology Expires: 18 Mar 2025	Documents	Participant Profile	Medical Status	Generate Full Report
9142004	Pathology Expires: 30 Jan 2025	Documents	Participant Profile	Medical Status	Generate Full Report